By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Genzyme Corporation 

500 Kendall Street

Cambridge  Massachusetts  02142  U.S.A.
Phone: 617-252-7500 Fax: 617-252-7600


SEARCH JOBS

About Genzyme

Genzyme is committed to discovering and delivering transformative therapies for patients with rare and special unmet medical needs, providing hope where there was none before.

Genzyme has pioneered the development and delivery of transformative therapies for over 30 years. Founded in 1981 in Boston, Massachusetts, Genzyme evolved from a tiny start-up with just a handful of employees to one of the world's leading biotech companies. Acquired by Sanofi in 2011, Genzyme now benefits from the reach and resources of one of the world’s largest pharmaceutical companies, with a shared commitment to improving the lives of patients.

Genzyme has long been known for our expertise in the class of rare genetic diseases known as lysosomal storage disorders (LSDs). LSDs remain the heart of our company today, but we have also expanded – through both in-house development and strategic acquisitions and partnerships – to other disease areas such as thyroid cancer and multiple sclerosis.

Learn more at www.jobsatgenzyme.com.

Follow our jobs on Twitter www.twitter.com/genzymejobs.

Follow us on LinkedIn http://www.linkedin.com/company/genzyme.

About Sanofi

Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets, and animal health. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).


Key Statistics


Email: AskGenzyme@genzyme.com
Ownership: Subsidiary

Web Site: Sanofi Genzyme
Employees:
Symbol: SNY
 



Industry
Biotechnology


Collaborations

Medtronic  Cardiac Cell Therapy

Cambridge Antibody Technology (CAT)  Antibodies against TGF-ß

Dyax  Hereditary Angioedema

Alnylam 





Company News
Sanofi Genzyme (SNY) Announces Start Of Phase III Study Of Isatuximab For Relapsed And Refractory Multiple Myeloma 12/5/2016 11:16:30 AM
Sanofi Genzyme (SNY) Release: Nova Scotia Includes LEMTRADA (Alemtuzumab) On Provincial Drug Program For Eligible Patients 12/2/2016 11:48:02 AM
Booming Shire (SHPG) to Take Over Sanofi Genzyme (SNY)'s HQ in Kendall Square, Eyes Hiring Another 400 Employees 11/22/2016 5:29:57 AM
Sanofi Genzyme (SNY) Release: Pivotal Phase 3 Trial Of NeoGAA Investigational Second-Generation Therapy For Pompe Disease To Begin In The UK 11/17/2016 8:34:51 AM
Sanofi Genzyme (SNY) Says 'We're In' to Alnylam (ALNY), Invests $100 Million to Late-Stage RNAi Hemophilia Trial 11/14/2016 6:53:07 AM
Sanofi Genzyme (SNY) Begins Pivotal Phase III Trial Of Neogaa Investigational Second-Generation Therapy For Pompe Disease 11/4/2016 11:28:32 AM
Sanofi Genzyme (SNY) Release: Pivotal Phase 2/3 Trial Of Olipudase Alfa For Adult Patients With Acid Sphingomyelinase Deficiency (Niemann-Pick Disease Type B) To Begin In The UK 11/3/2016 8:33:38 AM
Former Sanofi Genzyme (SNY) Exec to Helm CRISPR/Cas9 Developer Casebia Therapeutics 11/1/2016 8:36:56 AM
Deficiencies Found at Manufacturing Site Could Delay Approval of Sanofi Genzyme (SNY)'s Next Blockbuster 10/28/2016 5:49:41 AM
BARDA Awards $37.6 Million Contract To Sanofi Genzyme (SNY) To Supply Leukine (Sargramostim) For Potential Public Health Emergency 10/7/2016 11:27:58 AM
12345678910...
//-->